# OnCo record t-cell-exhaustion-term (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/t-cell-exhaustion-term/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "t-cell-exhaustion-term" ;
  schema:name "T-cell exhaustion and CAR-T persistence"@en ;
  schema:alternateName "exhaustion"@en, "exhausted T cells"@en, "T-cell fitness"@en, "T cell fitness"@en, "T-cell dysfunction"@en, "CAR-T persistence"@en, "CAR persistence"@en, "CAR-T expansion"@en, "peak expansion"@en, "in vivo expansion"@en, "B-cell aplasia"@en, "loss of persistence"@en, "memory phenotype"@en, "stem-like T cells"@en ;
  schema:description "Immune T cells that have been fighting too long become 'exhausted': sluggish, covered in inhibitory receptors, unable to kill. It limits both the patient's natural anti-tumour response and how long engineered CAR-T cells keep working (persistence)."@en ;
  schema:url <https://onco.cc/terms/t-cell-exhaustion-term/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/T_cell_exhaustion> ;
  schema:citation <https://en.wikipedia.org/wiki/T_cell_exhaustion> ;
  onco:related <https://onco.cc/terms/antigen-escape/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/hypogammaglobulinaemia/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/armored-car/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/tim3/>, <https://onco.cc/targets/tigit/>, <https://onco.cc/targets/cd57/>, <https://onco.cc/targets/cd69/> ;
  onco:drugs <https://onco.cc/drugs/favezelimab/>, <https://onco.cc/drugs/fianlimab/>, <https://onco.cc/drugs/hlx26/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/azd7789/>, <https://onco.cc/drugs/lb1410/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/hb0036/>, <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/tiragolumab/>, <https://onco.cc/drugs/domvanalimab/>, <https://onco.cc/drugs/vibostolimab/> ;
  onco:trials <https://onco.cc/trials/checkmate-142/>, <https://onco.cc/trials/checkmate-358/>, <https://onco.cc/trials/fianlimab-phase3-melanoma/>, <https://onco.cc/trials/i-spy-2/>, <https://onco.cc/trials/nct03486873/>, <https://onco.cc/trials/nct03899155/>, <https://onco.cc/trials/nct03916627/>, <https://onco.cc/trials/nct04082364/>, <https://onco.cc/trials/nct04165070/>, <https://onco.cc/trials/nct04524871/>, <https://onco.cc/trials/nct04590326/>, <https://onco.cc/trials/nct04626479/>, <https://onco.cc/trials/nct04626518/>, <https://onco.cc/trials/nct04655976/>, <https://onco.cc/trials/nct04665856/>, <https://onco.cc/trials/nct04736173/>, <https://onco.cc/trials/nct04895722/>, <https://onco.cc/trials/nct04931654/>, <https://onco.cc/trials/nct04938817/>, <https://onco.cc/trials/nct04995523/>, <https://onco.cc/trials/nct05009069/>, <https://onco.cc/trials/nct05123482/>, <https://onco.cc/trials/nct05211895/>, <https://onco.cc/trials/nct05224141/>, <https://onco.cc/trials/nct05287113/>, <https://onco.cc/trials/nct05329766/>, <https://onco.cc/trials/nct05417321/>, <https://onco.cc/trials/nct05489211/>, <https://onco.cc/trials/nct05502237/>, <https://onco.cc/trials/nct05565378/>, <https://onco.cc/trials/nct05608291/>, <https://onco.cc/trials/nct05625399/>, <https://onco.cc/trials/nct05633667/>, <https://onco.cc/trials/nct05645692/>, <https://onco.cc/trials/nct05676931/>, <https://onco.cc/trials/nct05702229/>, <https://onco.cc/trials/nct05724563/>, <https://onco.cc/trials/nct05775159/>, <https://onco.cc/trials/nct05785767/>, <https://onco.cc/trials/nct05787613/>, <https://onco.cc/trials/nct05800015/>, <https://onco.cc/trials/nct05805501/>, <https://onco.cc/trials/nct05845814/>, <https://onco.cc/trials/nct05904886/>, <https://onco.cc/trials/nct05970497/>, <https://onco.cc/trials/nct06062420/>, <https://onco.cc/trials/nct06101134/>, <https://onco.cc/trials/nct06109779/>, <https://onco.cc/trials/nct06161441/>, <https://onco.cc/trials/nct06190951/>, <https://onco.cc/trials/nct06205836/>, <https://onco.cc/trials/nct06246916/>, <https://onco.cc/trials/nct06264180/>, <https://onco.cc/trials/nct06342037/>, <https://onco.cc/trials/nct06349980/>, <https://onco.cc/trials/nct06357533/>, <https://onco.cc/trials/nct06467357/>, <https://onco.cc/trials/nct06468358/>, <https://onco.cc/trials/nct06472076/>, <https://onco.cc/trials/nct06521567/>, <https://onco.cc/trials/nct06561386/>, <https://onco.cc/trials/nct06564844/>, <https://onco.cc/trials/nct06627647/>, <https://onco.cc/trials/nct06692738/>, <https://onco.cc/trials/nct06697197/>, <https://onco.cc/trials/nct06727565/>, <https://onco.cc/trials/nct06764875/>, <https://onco.cc/trials/nct06769698/>, <https://onco.cc/trials/nct06787612/>, <https://onco.cc/trials/nct06865339/>, <https://onco.cc/trials/nct06868277/>, <https://onco.cc/trials/nct06921785/>, <https://onco.cc/trials/nct06943820/>, <https://onco.cc/trials/nct06963905/>, <https://onco.cc/trials/nct06989112/>, <https://onco.cc/trials/nct06996782/>, <https://onco.cc/trials/nct07058012/>, <https://onco.cc/trials/nct07069712/>, <https://onco.cc/trials/nct07098338/>, <https://onco.cc/trials/nct07115043/>, <https://onco.cc/trials/nct07221253/>, <https://onco.cc/trials/nct07224022/>, <https://onco.cc/trials/nct07281768/>, <https://onco.cc/trials/nct07431281/>, <https://onco.cc/trials/nct07492680/>, <https://onco.cc/trials/nct07720284/>, <https://onco.cc/trials/relativity-047/>, <https://onco.cc/trials/relativity-098/> .